Age-Related Macular Degeneration (AMD) is the most common cause of legal blindness in developed countries in the over-50s. One of the distinguishing characteristics of the early and intermediate stages of the disease are drusen. These are yellowish deposits, composed principally of lipids and proteins, which are formed in the retina and contribute to the development of AMD.
There are indications that abnormal levels of systemic cholesterol may be linked to the formation of drusen. This is why the Barcelona Macula Foundation (BMF) in conjunction with the Institut de la Màcula (IM) will conduct a study to determine whether the use of high doses of statins (drugs that inhibit the biosynthesis of cholesterol) lead to a regression or reduction in the volume and number of drusen in patients with intermediate AMD after 24 months.
This project, entitled STATINS4DRUSEN, may help to provide a new therapy that delays the progression of AMD, which is the priority aim of much research being conducted throughout the world.